Furthermore, a note of caution when treating COVID-19 patients with CP is the potential risk of ADE likely linked to early seroconversion prior to virus clearance with an enhancement of macrophage-dependent inflammatory damage by non-neutralizing antibodies. This evidence concerns the gene CP and COVID-19.